Targeting BCL-2 in Hematological Cancers: Computational Screening of Cucurbitacins as Promising Inhibitors

Fatemah Abdulaziz Alhakami

Abstract


Background: Disrupting the balance between cell proliferation and death is critical in cancer formation. Increased resistance to apoptosis, which is frequently caused by BCL-2 overexpression, is a critical oncogenic mechanism in many hematologic malignancies, notably lymphoid neoplasias. Overexpression of anti-apoptotic BCL-2 proteins is frequent in many malignancies, prompting the development of BCL-2 inhibitors as therapeutic agents.

Methods: In this study, cucurbitacin compounds were screened against BCL-2 using in silico PyRx tool to find strong natural inhibitors for treating hematological malignancies. ADMET-AI web interface was used to analyze ADMET properties of hit compounds. 

Results: Cucurbitacin O, IIb, K, and H were effective BCL-2 inhibitors, with binding energies ranging from
-8.0 to -8.8 kcal/mol, similar to the control compound (-7.9 kcal/mol). These compounds interacted with key amino acid residues in BCL-2. The radial graphs showed that all four compounds had good ADMET characteristics. The compounds have a high probability of being safe for the blood-brain barrier and pose a low risk of hERG channel blockage. Furthermore, they have higher oral bioavailability and adequate water solubility. Their minimal clinical toxicity profiles indicate their potential safety in therapeutic applications.

Conclusion: Cucurbitacin O, IIb, K, and H can be employed as BCL-2 inhibitors to manage hematological malignancies. However, further experimental studies are needed to validate these compounds as BCL-2 inhibitors.

Keywords: Cancer; Apoptosis; BCL-2; Cucurbitacin compounds; Drug-likeness  


Full Text:

PDF

References


Reed JC. Apoptosis-based therapies. Nature Reviews Drug Discovery, (2002); 1(2): 111-121.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, (2011); 144(5): 646-674.

Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood, (1997); 89(6): 1845-1853.

Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Current Opinion in Oncology, (2013); 25(1): 50-51.

Arici R, Kemal AK, Pabuccuoğlu S, Birler S, Demir K, et al. Effects of melatonin addition to the cold storage medium on cumulus oocyte complex apoptosis, viability and in vitro maturation rates of cat oocytes. Kafkas Üniversitesi Veteriner Fakültesi Dergisi. (2022) ; 28(2): 193-200.

Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science, (1985); 229(4720): 1390-1393.

Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nature Reviews Drug Discovery, (2008); 7(12): 989-1000.

Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature, (1988); 335(6189): 440-442.

Roberts AW, Huang D. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. Clinical Pharmacology & Therapeutics, (2017); 101(1): 89-98.

Billard C. BH3 mimetics: status of the field and new developments. Molecular Cancer Therapeutics, (2013); 12(9): 1691-1700.

Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annual Review of Biophysics and Biomolecular Structure, (2000); 29: 291-325.

Pfisterer JHK, Liang Y, Schneider O, Bandarenka AS. Direct instrumental identification of catalytically active surface sites. Nature, (2017); 549(7670): 74-77.

Gu R, Wu F, Huang Z. Role of Computer-Aided Drug Design in Drug Development. Molecules, (2023); 28(20): 7160.

Yu W, MacKerell AD, Jr. Computer-Aided Drug Design Methods. Methods in Molecular Biology, (2017); 1520: 85-106.

Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget, (2018); 9(28): 20075-20088.

Gimeno A, Ojeda-Montes MJ, Tomas-Hernandez S, Cereto-Massague A, Beltran-Debon R, et al. The Light and Dark Sides of Virtual Screening: What Is There to Know? International Journal of Molecular Sciences, (2019); 20(6): 1375.

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology, (2015); 1263: 243-250.

Swanson K, Walther P, Leitz J, Mukherjee S, Wu JC, et al. ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. Bioinformatics, (2024); 40(7): btae416.

Yang S, Mao Y, Zhang H, Xu Y, An J, Huang Z. The chemical biology of apoptosis: Revisited after 17 years. European Journal of Medicinal Chemistry, (2019); 177: 63-75.

Sait KHW, Alam Q, Anfinan N, Al-Ghamdi O, Malik A, et al. Structure-based virtual screening and molecular docking for the identification of potential novel EGFRkinase inhibitors against ovarian cancer. Bioinformation, (2019); 15(4): 287-294.

Nazam N, Lone MI, Hamid A, Qadah T, Banjar A, et al. Dimethoate Induces DNA Damage and Mitochondrial Dysfunction Triggering Apoptosis in Rat Bone-Marrow and Peripheral Blood Cells. Toxics, (2020); 8(4): 80.

Sait KHW, Mashraqi M, Khogeer AA, Alzahrani O, Anfinan NM, et al. Molecular docking analysis of HER-2 inhibitor from the ZINC database as anticancer agents. Bioinformation, (2020); 16(11): 882-887.

Alqahtani LS, Alkathiri AS, Alzahrani A, Alghamdi RM, Alamri WA, et al. Structure-Based Virtual Screening of Antiviral Compounds Targeting the Norovirus RdRp Protein. Advancements in Life Sciences, (2024); 11(2): 488-492.

Shaikh S, Aaqil H, Rizvi SMD, Shakil S, Abuzenadah AM, et al. Comparative inhibition study of compounds identified in the methanolic extract of Apamarga Kshara against Trichomonas vaginalis carbamate kinase (TvCK): an enzoinformatics approach. Interdisciplinary Sciences: Computational Life Sciences, (2016); 8: 357-365.

Varela C, Melim C, Neves BG, Sharifi-Rad J, Calina D, et al. Cucurbitacins as potential anticancer agents: new insights on molecular mechanisms. Journal of Translational Medicine, (2022); 20(1): 630.

Zieniuk B, Pawelkowicz M. Recent Advances in the Application of Cucurbitacins as Anticancer Agents. Metabolites, (2023); 13(10): 1081.

Li Y, Li Y, Yao Y, Li H, Gao C, et al. Potential of cucurbitacin as an anticancer drug. Biomedicine & Pharmacotherapy, (2023); 168: 115707.

Zhang ZR, Gao MX, Yang K. Cucurbitacin B inhibits cell proliferation and induces apoptosis in human osteosarcoma cells via modulation of the JAK2/STAT3 and MAPK pathways. Experimental and Therapeutic Medicine, (2017); 14(1): 805-812.

Tuli HS, Rath P, Chauhan A, Ranjan A, Ramniwas S, et al. Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends. Biomolecules, (2022); 13(1): 57.




DOI: http://dx.doi.org/10.62940/als.v12i2.3634

Refbacks

  • There are currently no refbacks.